Cytokine Release Syndrome Clinical Trials

8 recruitingLast updated: June 21, 2026

There are 8 actively recruiting cytokine release syndrome clinical trials across 9 countries. Studies span Phase 1, Not Applicable, Phase 2, Early Phase 1. Top locations include Augusta, Georgia, United States, Bad Oeynhausen, Germany, Barcelona, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Cytokine Release Syndrome Trials at a Glance

8 actively recruiting trials for cytokine release syndrome are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Augusta, Bad Oeynhausen, and Barcelona. Lead sponsors running cytokine release syndrome studies include Institute of Hematology & Blood Diseases Hospital, China, CytoSorbents, Inc, and CytoAgents, Inc..

Browse cytokine release syndrome trials by phase

Treatments under study

About Cytokine Release Syndrome Clinical Trials

Looking for clinical trials for Cytokine Release Syndrome? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytokine Release Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytokine Release Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Not Applicable

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Hematologic CancerCRS - Cytokine Release Syndrome
Rigshospitalet, Denmark100 enrolled1 locationNCT06377059
Recruiting
Phase 1Phase 2

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Cytokine Release Syndrome
CytoAgents, Inc.54 enrolled6 locationsNCT05905328
Recruiting
Early Phase 1

Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome

CRS - Cytokine Release SyndromeHLH
University of Pennsylvania10 enrolled1 locationNCT05306080
Recruiting
Not Applicable

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

LymphomaMyelomaCytokine Release Syndrome+1 more
University of Utah40 enrolled1 locationNCT07390071
Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

SepsisLiver Transplant; ComplicationsPancreatitis+15 more
CytoSorbents, Inc3,000 enrolled28 locationsNCT05146336
Recruiting
Phase 1

Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Cytokine Release SyndromeICANS
Institute of Hematology & Blood Diseases Hospital, China18 enrolled1 locationNCT07169487
Recruiting
Phase 2

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

MyelomaCRS - Cytokine Release Syndrome
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106671
Recruiting
Phase 1

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Non-Hodgkin LymphomaCytokine Release Syndrome
Taylor Brooks20 enrolled1 locationNCT06447376